Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Octylphenol Polyoxyethylene Ether 9, known in labs and factories as OP-9, traces its roots back to the chemical innovations of the early 20th century. Chemists searching for effective nonionic surfactants in the booming industrial era stumbled upon alkylphenol ethoxylation, leading to a family of compounds that changed how industries handled emulsification and wetting problems. During the post-war surge in pharmaceutical and cosmetic production, companies sought functional materials that could dissolve oils and stabilize products. OP-9 soon grabbed attention thanks to its balance between hydrophilic and lipophilic properties, a direct result of adding nine ethylene oxide units to octylphenol. In those days, chemists moved fast, sometimes with little regard for environmental or safety factors. But OP-9’s utility rapidly spread from textiles and detergents into the medical world, especially as regulatory bodies tightened requirements for quality and purity in pharmaceutical excipients. Its journey embodies both the promise and pitfalls of synthetic chemistry, evolving through decades of research, innovation, and regulatory scrutiny.
OP-9 lands on distributor shelves with a clear promise: an efficient, high-purity nonionic surfactant. Its reputation in BP, EP, and USP pharma grades comes from batches produced under strict standards, focusing on batch-to-batch consistency and documented purity. You’ll see it listed under pharmaceutical auxiliaries, used where reliable solubilization and emulsification are critical. For me, years spent running quality checks in a pharmaceutical lab have shown that an OP-9 lot can make or break a stable formulation, especially for injectables or sensitive topical creams. The right grade helps ensure products pass dissolution, clarity, and stability testing. OP-9’s flexibility extends into other fields: making emulsions in agrochemicals, synthetics in cleaners, and toner dispersions in printing. Over time, it’s become a workhorse in the background, taken for granted by product developers confident in its performance and reliability.
OP-9 usually shows up as a pale yellow liquid or viscous paste, with a faint, easily recognizable odor typical of ethoxylated phenols. Its average molecular weight climbs in step with the number of ethylene oxide units, and for OP-9, nine units provide a balance between water solubility and oil compatibility. Surface tension reduction is one of its main tricks, making it invaluable for formulations needing rapid wetting or spreading. Chemically, OP-9 handles acidic and mildly basic environments without breaking down, which broadens its application potential. I’ve found the cloud point – the temperature where it loses solubility and forms a cloudy suspension – particularly significant. In cleanroom work, solutions need to remain clear at working temperatures; the cloud point of OP-9 suits this world unlike shorter EO derivatives that phase out too soon. Its critical micelle concentration puts it in a sweet spot for achieving stable dispersions without overdosing, and its resistance to oxidation means minimal impact on shelf life.
Pharma-grade OP-9 demands tight specifications: minimum purity often above 99%, residual octylphenol and dioxane levels below stringent thresholds, and well-documented heavy metal screenings. Labels should clearly display batch numbers, manufacturing and expiry dates, storage conditions, and a breakdown of possible contaminants, aligning with BP, EP, and USP monographs. Laboratories and manufacturers rely on this documentation, not just for compliance but for assurance against process interruptions. Having worked through audits myself, a traceable and well-documented OP-9 bottle makes paperwork and product recalls far less likely. This transparency reassures not only regulators but clinicians and end-users who rely on safe excipients in drug formulations.
Making OP-9 means starting with para-tert-octylphenol, feeding it into a reactor with ethylene oxide, and relying on an alkaline catalyst. The process requires strict temperature and pressure control to avoid runaway reactions, off-target ethoxylation, or dangerous by-products like 1,4-dioxane. Plant engineers face a challenge balancing throughput and consistent degree of ethoxylation; too little and the product won’t perform as a surfactant, too much and it loses its ability to interact with oils. My own time troubleshooting production hiccups taught me that subtle tweaks in temperature ramp rates or EO feed speed can cause wild swings in product characteristics, so well-tuned process control systems stand between usable product and expensive scrap. Following the reaction, purification steps like vacuum stripping and filtration bring the product within medical-grade standards. These steps keep OP-9 suitable for pharmaceutical use, where small impurities can disrupt a product’s function or safety.
OP-9, by itself, serves well in various emulsification and solubilization jobs, but chemical modification can tailor it further. Sulfation or phosphorylation, for instance, leads to anionic derivatives used in specialty formulations where charge interacts differently with biological membranes. Crosslinking or reacting with reactive dyes also brings OP-9 into the textile and colorant industries, where its surfactant backbone helps solubilize or disperse organic molecules. In production environments, OP-9’s reactivity sometimes presents a challenge; uncontrolled side reactions can boost impurity loads or damage catalyst beds, raising costs down the line. The interplay between OP-9 and active pharmaceutical ingredients also gets constant re-evaluation as manufacturers move towards biologics and new delivery systems, where excipient-API compatibility isn’t guaranteed by tradition alone. Chemists and formulators keep probing new modifications to broaden the range of stable, effective products coming out of modern factories.
Within the research community and industry, OP-9 pops up under many banners: Ethoxylated Octylphenol, Octylphenoxypolyethoxyethanol, and CAS numbers like 9036-19-5. Some trade names reflect manufacturer-specific nuances, but the underlying product fits the OP-9 description by degree of ethoxylation and feedstock chemistry. This convoluted naming sometimes leads to errors in procurement or regulatory filings, either through supplier confusion or mismatched labelling conventions. Wise researchers and purchasing managers check certificates of analysis and detailed method sheets to confirm identity before adding any drum to inventory, because a mix-up with a similar-sounding surfactant can derail both research and scaled-up production.
Safety becomes top priority in any environment dealing with OP-9, especially since its starting material, octylphenol, ranks as an endocrine disruptor and environmental contaminant. Current best practices in both pharma and chemical plants dictate full personal protective equipment, solvent-rated ventilation, and continuous spill containment measures. Toxicity data highlight risks through skin absorption and inhalation of aerosols, so high-volume transfer points need careful engineering controls and real-time monitoring. Regulations now demand limits on unreacted monomers, dioxane, and heavy metals in final products for pharmaceutical use. As regulations tighten, many plants replace outdated glassware or pipelines with steel and lined systems that stand up to both chemicals and cleaning regimens. From my years supervising blending operations, routine staff training and clear safety data makes a measurable difference in workplace incidents and quality deviations. Companies that ignore rigorous operational discipline invite costly accidents that stain reputations and trust.
Few chemical intermediates have as broad a reach as OP-9. In pharma, it acts as an emulsifier, dispersant, and solubilizer for everything from oral suspensions to parenteral injections, especially where stability against precipitation spells the difference between a successful dose and a rejected batch. In specialty coatings, it enables pigment dispersion, improving product appearance and performance. The cosmetics sector values OP-9 for gentle skin feel and the ability to stabilize volatile essential oils, which push the boundaries of creative product developers. My own foray into agricultural formulations revealed OP-9’s knack for making pesticides not just stick to plants, but also mix more evenly in the tank, helping farmers see fewer clogged nozzles and wasted treatments. It’s also found in cleaning formulations, inks, and latex polymerizations, a testament to how one surfactant, engineered for balance, can cross industrial lines and solve deeply practical issues for different users.
R&D teams keep pushing the boundaries of OP-9 use. Modern studies focus on optimizing its compatibility with sensitive or high-value actives, especially biologics and specialty drugs that struggle with solubility or shelf life. Technologists explore greener synthetic routes, such as enzymatic or solid-catalyst procedures, to minimize environmental impact and purification needs. Analytical chemists dig deeper into impurity profiles with high-performance liquid chromatography and advanced spectroscopy, helping to correlate surfactant structure with effects on finished products. In my time partnering with university laboratories, novel OP-9 analogs often show unexpected perks: quicker wetting, better biocompatibility, or lower toxicity. Researchers also investigate alternate uses in targeted drug delivery, nanomaterials, and controlled-release systems, hoping the right surfactant unlocks doors to better therapies or products. The push continues for sustainable packaging and biodegradable derivatives, pushing the industry toward a cleaner chemical legacy without giving up on performance or affordability.
OP-9 stands under a bright regulatory microscope for a reason. Its parent compound, octylphenol, posts a clear risk as a hormone disruptor and aquatic ecotoxin. As a result, industry and academia devote real effort to toxicity profiling and risk mitigation. Standard battery tests for dermal, oral, and inhalation hazards help authorities set occupational and environmental limits. Chronic exposure studies in rodents give clues about long-term effects as regulators debate restrictions and phase-out schedules in higher-risk applications. Clean-up procedures and effluent standards reflect the persistent nature of phenolic compounds; operators need to invest in capture, treatment, and monitoring technology. Over the years, I’ve seen stakeholders respond to new toxicity evidence by tightening material handling and documentation, even switching to alternative surfactants when justified. Collaboration among manufacturers, toxicologists, and environmental scientists stays key to limiting risks to both humans and ecosystems.
Surfactant technology isn’t standing still, and OP-9 sits at an inflection point. Regulatory and market trends point toward lower-toxicity alternatives and renewable feedstocks, driven by both public concern and stricter laws. Innovations in synthetic chemistry promise to reduce impurities and push performance boundaries, opening up niches in novel drug delivery systems and more advanced material engineering. Companies investing in greener derivatives or closed-loop production facilities stand poised to meet both sustainability targets and rising demand in emerging economies. In my experience, success will hinge on being transparent with data, investing in continual research, and keeping an open dialogue between producers, regulators, and downstream users. Demand for safe, reliable surfactants remains strong, so the next generation of OP-9 and its analogs could very well define a new standard for both safety and performance in the years ahead.
Octylphenol Polyoxyethylene Ether 9, often called Op-9, belongs to a family of chemicals recognized for their surfactant properties. The compound carries both water-loving and oil-loving segments, making it effective for mixing substances that often resist being blended. People working in laboratories or production facilities often call on surfactants like Op-9 to keep formulations stable and predictable. You’ll find Op-9 as a pasty or oily liquid, almost invisible by smell, and dissolvable in most organic solvents and water.
In the pharmaceutical world, solubility can make or break a drug’s journey from the lab bench to the pharmacy shelf. Sometimes, the most promising compounds struggle to dissolve well enough for use in a pill or liquid medicine. Here’s where Op-9 goes to work. Its structure boosts solubility for a wide range of drug compounds. I’ve seen drug formulators use Op-9 to coax stubborn powders into liquids, letting medicines reach the bloodstream more efficiently and predictably.
Beyond solubility, Op-9 helps create stable emulsions. Certain creams and ointments depend on oil and water mixing smoothly—impossible without a surfactant. Manufacturers add Op-9, knowing patients expect lotions to glide on instead of clumping up or separating in storage.
Research teams usually pay attention to Op-9’s ability to act as a wetting agent. Wetting agents help liquids spread more evenly across surfaces, which matters for tablets designed to dissolve quickly inside the body, or skin creams meant to be absorbed instead of just sitting on the surface.
Op-9 also assists in keeping solid or liquid ingredients suspended in solutions. This is valuable for injectable medicines—no one wants to find clumps inside a syringe. Anyone who’s drawn up an injection knows the importance of full, even mixing.
Like any chemical used in the process of making medicine, the sources and purity of Op-9 require routine checks. Traces of byproducts could threaten patient safety or drug reliability. Regulators demand proof that each batch meets tough standards for cleanliness and performance, so pharmaceutical companies stick to suppliers they trust.
The environmental impact of surfactants like Op-9 sparks plenty of discussion within the industry. Scientists and policy makers grow cautious after realizing that some nonylphenol and octylphenol derivatives linger in water and soil, where they might disrupt wildlife. Leading manufacturers have started exploring ways to reduce run-off or to design greener ingredients. Still, the balancing act between environmental responsibility and product quality continues.
It’s true that Op-9, on its own, can’t solve every formulation problem. Still, it opens more doors than many realize, especially when working with tough-to-mix or hard-to-dissolve compounds. In practical terms, Op-9 boosts the number of drugs that reach pharmacy shelves—and by extension, the number of people treated. Even so, developers need to pair its use with careful quality checks and look toward bio-based, biodegradable options for future formulas. Any chemist or product developer with a conscience knows the story doesn’t end with better drug performance—it grows with stewardship over human health and the health of the planet.
In the pharmaceutical world, every milligram carries weight. People who need medicine rely on trust, and a big chunk of that rests on what’s actually blended and bottled. That’s where pharma grades like BP, EP, or USP become more than initials—they’re the badges proving a substance meets strict quality demands. With so much at stake, it makes sense to look at whether Op-9 BP EP USP Pharma Grade lines up with international rules set by groups like the British Pharmacopoeia (BP), European Pharmacopoeia (EP), and United States Pharmacopeia (USP).
Let’s break this down: being labeled BP, EP, or USP isn’t just about hitting purity numbers. Each group publishes books thicker than most folks’ arms, loaded with tests for identity, chemical limits, benchmark grades, and packaging rules. They spell out everything from allowed impurities to how to test the color or pH. Sometimes, one pharmacopoeia nudges limits tighter than the others. If a supplier claims Op-9 checks all these boxes, the paperwork needs to back it up.
I’ve dealt with pharmaceutical ingredients for years. Fact is, I’ve seen “pharma grade” thrown around at trade shows where vendors hand out glossy sheets, but there’s no Certificate of Analysis, much less third-party lab proof. It’s easy to slap on grades, harder to deliver documentation matching each pharmacopoeia’s requirements—let alone all three at once.
If Op-9 carries triple ratings—BP, EP, and USP—buyers should see batch records, methods for each test, and signatures from qualified analysts. Each pharmacopeia checks identity, purity, and safety, but sometimes the acceptable residual solvents or heavy metals levels differ. For example, the USP may look at organic volatile impurities differently from the EP. Certification across major markets calls for a close look at every detail. A product might hit the bar for one and miss it for another by a hair.
Labs offering Op-9 at such grade levels have to keep up with updates. Pharmacopoeias evolve all the time, adding or amending chapters on microbial contamination or new elemental impurities limits. As regulators increase scrutiny, especially since the pandemic spotlighted global supply chains, suppliers have to show their testing is current and aligns with new standards. No shortcuts work here. Regulators in Europe may inspect facilities for GMP compliance, while the US FDA looks for data integrity in lab records. One missed step in documentation, and it can spell trouble for finished products or even endanger patient safety.
For drug makers, relying on a well-documented supply chain avoids scary surprises. Here, transparency wins out—request detailed batch-specific documents and cross-check with the BP, EP, and USP monographs. If a supplier hesitates, look elsewhere. Manufacturers who involve themselves in supplier audits, invest in third-party verification, and maintain open lines with regulatory bodies tend to build trust and avoid costly recalls or regulatory pushback.
Genuine pharma compliance lives in documentation, reliable test results, and transparent sourcing. Op-9 can play a strong role in international markets, as long as claims of BP, EP, or USP status mean more than marketing. Real compliance means showing the receipts—always.
Op-9, a non-ionic surfactant often sold under names like octylphenol ethoxylate, brings unique challenges and advantages. Water isn’t its best friend. At room temperature, it only dissolves at low concentrations. Once you push higher concentrations, Op-9 tends to get cloudy, sometimes turning an entire solution milky. That signals an incompatibility problem with plain aqueous solutions. Most labs I know mix it in at warm temperatures or pre-dilute in a co-solvent like ethanol to get anything close to a stable mixture. In cases where someone needs a clear solution and water is the base, Op-9 usually steps back in favor of more water-loving surfactants.
Move over to alcohols and glycols, and Op-9 starts behaving much better. Ethanol or propylene glycol picks up the slack, letting Op-9 blend smoothly. Many companies handle granulation or liquid processing in these media because the surfactant actually dissolves completely. Organic solvents open up more space for Op-9, so you see clearer solutions and more reliable uptake. This quality comes into play for gels, creams, and ointments designed to blend both water and fat-loving ingredients.
Oil and fat-based pharmaceuticals often present solubility puzzles. Op-9 easily mixes with most oils—mineral, vegetable, and medium-chain triglycerides. It acts as a bridge molecule, letting oily ingredients join up with watery ones. This property leads to its frequent use in creams and lotions, where someone wants both oil and water in the same bottle or tube. My experience shows Op-9 stabilizes these challenging blends, stopping separation over time. Real-world tests on storage samples back this up: properly balanced Op-9 levels cut down on product breakdown and give longer shelf life.
Pharmaceuticals rarely just mix surfactants and solvents. Many actives may be sensitive to certain excipients. Op-9 usually remains neutral. It doesn’t “grab” onto most drugs or trigger unexpected clotting or gelling. A few exceptions pop up—proteins and peptides sometimes clump in the presence of Op-9, especially at high concentrations. Vitamin C, folic acid, and some antibiotics break down faster when surfactants aren’t balanced right. Pharmacists often run stability trials, blending Op-9 with each active to spot any trouble before products go out to market.
Solid tablets add another layer of challenge. Op-9 mixes best with other excipients before granulation, but only in low doses. Too much, and the batch gets sticky, causing granules to clump during compression. This slows down production and can ruin uniformity in the dose. Most pill makers keep Op-9 concentrations just enough for what’s needed—often less than 1% by weight. Higher levels don’t just affect physical properties; they sometimes speed up the dissolution of tablets, which isn’t always welcome from a controlled release perspective.
Anyone working with Op-9 must lean on solid pre-formulation studies. Combining small-scale tests, thermal cycling, and stability screening helps avoid compatibility disasters later. Switching to more hydrophilic surfactants or using Op-9 as part of a blend with other emulsifiers can dodge some common issues. Finally, clear labeling and ongoing monitoring keep surprises at bay, especially for sensitive or regulated pharmaceuticals.
Op-9 pops up across industries from agriculture to manufacturing, somewhere between convenience and hazard. Working with Op-9, I realized that taking shortcuts never plays well. Even a seasoned hand can get complacent, forgetting this isn’t just another harmless chemical blend. The label “non-volatile” or “low-toxicity” means little once a spill happens in a cramped workspace without proper ventilation.
Eyewash stations and emergency showers matter. I watched a colleague rush for the nearest sink after a splash, face pale—not because Op-9 burned, but because the unknowns sat heavy in his mind. Gloves—nitrile, not the usual latex—should always cover your hands, and goggles beat safety glasses since even a light aerosol stings eyes. Standard work aprons hold up well to most routine tasks, but the right gear depends on both the amount handled and the likelihood of spills or splashes.
Repeated exposure, even at low levels, can stack up. The science points to skin and eye irritation, and in a few cases, respiratory concerns if the product mist spreads. No one wants to become the anecdote in a safety seminar, so simple practices go a long way. Avoid touching your face until gloves come off. Work in a space with exhaust fans or, at minimum, an open window. If skin contact occurs, wash up right away with soap and water, not just a quick rinse.
Training lies at the core of safe handling. Every team I’ve worked with spends a few minutes before shifts walking through the basics—the color-coded bottles, the “no-mix” policy with other chemicals, and the protocol for cleanup. Spills should be tackled fast using absorbent materials, tossing them in clearly marked hazardous waste bins. Even a minor spill can create a slippery surface, leading to falls.
The wrong container leads to headaches. Op-9 reacts with strong oxidizers or acids, setting off heat or unwanted byproducts. Stainless steel, polyethylene, or original manufacturer-approved packaging provides peace of mind. Double check lids seal tightly before stacking for storage. Never reuse old household bottles; lingering residues can spark trouble.
Temperature swings wreak havoc on chemicals. Keeping Op-9 at a steady temperature—generally cool and out of sunlight—prevents breakdown and irregular performance. My own experience taught me that even minor fluctuations in store rooms cause condensation or pressure build-up, which warps lids or, worse, cracks seams unnoticed till the next stock check.
Labeling must stay clear and updated, especially if bottles get topped off from bulk drums. Outdated markings lead to confusion and mistakes. Segregate Op-9 from incompatible substances; one mix-up can spell disaster. Every workplace needs a locked cabinet or restricted shelf where only trained staff access these chemicals. Security isn’t paranoia—it prevents theft, vandalism, or accidental misuse.
Routine audits work better than relying on memory. Log each move, each delivery, and each use. Safety Data Sheets (SDS) need to stay accessible—not buried in a forgotten binder. Up-to-date training, simple routines, and proper gear keep everyone safe. I always point out to new hires: it isn’t the big accident that will catch you, but the ignored step that accumulates until it turns into a real problem.
Pharmaceutical manufacturers and labs handle lots of materials that demand precision, and Op-9 Pharma Grade isn’t an exception. Most suppliers ship Op-9 in well-sealed containers. You’ll usually find 1 kg bottles for pilot projects, 5 kg cans for frequent users, and 25 kg drums for big production lines. Bulk containers over 50 kg do circulate, but those mainly suit really high-volume processing. Smaller bottles allow for tighter stock control and reduce exposure each time you open the package. In my own experience with bulk chemicals, mistakes often come from mixing up opened containers or skimping on fresh supplies—having manageable packaging keeps errors low and cuts down on waste.
One of the frustrations scientists mention is inconsistent packaging practices from various suppliers. Some folks spot differences in cap designs, liners, or even labeling. For those working under cGMP oversight or prepping for FDA audits, these details matter: shrink-wrapped, tamper-evident seals, and clear labels can either make or break compliance. If you’re buying for a regulated environment, pushing suppliers for packaging specs up front pays off.
Op-9 doesn’t last forever. Standard shelf life usually ranges from 12 months up to three years, though lots depend on storage conditions like light, humidity, and temperature. Cool, dry, and shaded racks stretch the lifespan. If materials degrade sooner than expected, you risk failed batches, extra costs, or unstable products.
Everyone in pharma has dealt with that one forgotten drum in the back of the storage room. If you’re working close to expiration, it makes sense to check with QC teams for retesting, and never trust a date blindly. So, storing chemicals responsibly and staying on top of inventory isn’t busy work—it’s a safeguard for quality.
Pharma-grade chemicals travel with a fair amount of paperwork. For Op-9, two documents stand out: Certificate of Analysis (COA) and Material Safety Data Sheet (MSDS).
A COA gives a detailed breakdown of tested parameters—identity, purity, heavy metal limits, microbial data, residual solvents. The supplier runs these tests on each batch, stamping the results and batch number so you can trace every bottle back to its origins. I’ve watched teams reject entire shipments because the COA didn’t match their specs.
The MSDS, soon to be more widely referred to as SDS (Safety Data Sheet), gives the rundown on handling risks, storage advice, first aid, fire reactions, and spill response. Even pros get caught off guard by changes in hazard classifications or overlooked incompatibilities. Reading—and reviewing—these sheets before use keeps people out of the emergency room.
Relying on trusted vendors pays dividends, especially with pharma raw materials. Ask for photos or samples of packaging before ordering. Set up robust incoming inspection—the best labs develop checklists based on the documentation, and keep digital backups. If you notice inconsistent labeling, unclear expiry dates, or absent COAs, press suppliers for better traceability.
In my own work, teams who build habits around tagging containers, double-checking paperwork, and rotation (FIFO—first in, first out) rarely scramble for recalls or regulatory corrections. Good systems beat last-minute heroics, every time.
| Names | |
| Preferred IUPAC name | 2-[2-(2-(2-(2-(2-(2-(2-(2-(octylphenoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy]ethanol |
| Other names |
Polyoxyethylene(9) octylphenyl ether Octylphenoxypolyethoxyethanol Triton X-100 Octylphenol ethoxylate Octoxynol-9 Polyethylene glycol mono(octylphenyl) ether |
| Pronunciation | /ˈɒk.tɪl.fiː.nɒl ˌpɒl.i.ɒk.siˌiː.θəˈliːn ˈiː.θər naɪn/ |
| Identifiers | |
| CAS Number | 9036-19-5 |
| Beilstein Reference | 1770804 |
| ChEBI | CHEBI:53027 |
| ChEMBL | CHEBI:81938 |
| ChemSpider | 110215-63-5 |
| DrugBank | DB11219 |
| ECHA InfoCard | echa-infoCard-100.225.048 |
| EC Number | 9036-19-5 |
| Gmelin Reference | Gmelin Reference: "85321 |
| KEGG | C07131 |
| MeSH | Chemical Actions and Uses; Nonionic Surfactants; Polyoxyethylenes; Octylphenols; Detergents |
| PubChem CID | 7012 |
| RTECS number | SLBOA65T3X |
| UNII | 3B9Z5P706B |
| UN number | UN3082 |
| CompTox Dashboard (EPA) | DTXSID0011547 |
| Properties | |
| Chemical formula | C26H44O10 |
| Molar mass | 646.9 g/mol |
| Appearance | Appearance: Colorless to light yellow transparent liquid |
| Odor | Odorless |
| Density | 0.982 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 4.2 |
| Acidity (pKa) | 7.0 |
| Basicity (pKb) | “pKb 5.4 (1% aq. soln. at 25 °C)” |
| Refractive index (nD) | 1.4550 |
| Viscosity | 80-110 mPa.s |
| Dipole moment | 4.30 D |
| Pharmacology | |
| ATC code | D06AX |
| Hazards | |
| Main hazards | Causes skin and eye irritation. Harmful if swallowed. Toxic to aquatic life with long lasting effects. |
| GHS labelling | GHS07, GHS09 |
| Pictograms | ⚗️💧🧪🔬 |
| Signal word | Warning |
| Hazard statements | H319: Causes serious eye irritation. |
| Precautionary statements | P261, P264, P272, P273, P280, P302+P352, P305+P351+P338, P333+P313, P337+P313, P362+P364 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | >145°C |
| Lethal dose or concentration | Lethal dose or concentration information for **Octylphenol Polyoxyethylene Ether 9 (Op-9) BP EP USP Pharma Grade** is typically given as: **LD50 (oral, rat): > 2000 mg/kg** |
| LD50 (median dose) | LD50 (median dose): 1800 mg/kg (rat, oral) |
| NIOSH | CAS 9036-19-5 |
| PEL (Permissible) | PEL: Not established |
| REL (Recommended) | 0.5% |
| IDLH (Immediate danger) | Not Established |
| Related compounds | |
| Related compounds |
Octylphenol Polyoxyethylene Ether 4 (Op-4) Octylphenol Polyoxyethylene Ether 10 (Op-10) Octylphenol Polyoxyethylene Ether 40 (Op-40) Nonylphenol Polyoxyethylene Ether Polyethylene Glycol (PEG) Nonidet P-40 Triton X-100 Cremophor EL |
Chengguan District, Lanzhou, Gansu, China
